Sinovac cuts full-year revenue forecast

Sinovac Biotech shares fell 10 percent Monday, a day after the vaccine manufacturer cut its full-year revenue forecast for the second time, citing continued weakness in Chinese demand for vaccines. "The vaccine market in China is experiencing a much longer than originally expected demand weakness in the market following the unfounded media reports about vaccine safety in China's Shanxi province," the company says in a release. Sinovac release | Report

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.